Open AccessIs Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer’s Perspective?
Author(s) -
Rachel H. Albright,
Robert M. Joseph,
Dane K. Wukich,
David G. Armstrong,
Adam E. Fleischer
Publication year - 2020
Publication title -
clinical orthopaedics and related research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.178
H-Index - 204
eISSN - 1528-1132
pISSN - 0009-921X
DOI - 10.1097/corr.0000000000001416
Subject(s) - medicine , amputation , quality adjusted life year , surgery , diabetic foot ulcer , deformity , cost effectiveness , physical therapy , diabetic foot , diabetes mellitus , risk analysis (engineering) , endocrinology
Charcot neuroarthropathy is a morbid and expensive complication of diabetes that can lead to lower extremity amputation. Current treatment of unstable midfoot deformity includes lifetime limb bracing, primary transtibial amputation, or surgical reconstruction of the deformity. In the absence of a widely adopted treatment algorithm, the decision to pursue more costly attempts at reconstruction in the United States continues to be driven by surgeon preference.